These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26925907)

  • 1. Risk Factors for Relapse of Human Brucellosis.
    Hasanjani Roushan MR; Moulana Z; Mohseni Afshar Z; Ebrahimpour S
    Glob J Health Sci; 2015 Nov; 8(7):77-82. PubMed ID: 26925907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans.
    Hasanjani Roushan MR; Mohraz M; Hajiahmadi M; Ramzani A; Valayati AA
    Clin Infect Dis; 2006 Apr; 42(8):1075-80. PubMed ID: 16575723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical profile and management of brucellosis in Tehran - Iran.
    Hadadi A; Rasoulinejad M; HajiAbdolbaghi M; Mohraz M; Khashayar P
    Acta Clin Belg; 2009; 64(1):11-5. PubMed ID: 19317236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature.
    Buzgan T; Karahocagil MK; Irmak H; Baran AI; Karsen H; Evirgen O; Akdeniz H
    Int J Infect Dis; 2010 Jun; 14(6):e469-78. PubMed ID: 19910232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiologic, clinical and laboratory findings of patients with brucellosis in Hamadan, west of Iran.
    Eini P; Keramat F; Hasanzadehhoseinabadi M
    J Res Health Sci; 2012 Dec; 12(2):105-8. PubMed ID: 23241521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for human brucellosis in Iran: a case-control study.
    Sofian M; Aghakhani A; Velayati AA; Banifazl M; Eslamifar A; Ramezani A
    Int J Infect Dis; 2008 Mar; 12(2):157-61. PubMed ID: 17698385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between doxycycline-rifampin-amikacin and doxycycline-rifampin regimens in the treatment of brucellosis.
    Ranjbar M; Keramat F; Mamani M; Kia AR; Khalilian FO; Hashemi SH; Nojomi M
    Int J Infect Dis; 2007 Mar; 11(2):152-6. PubMed ID: 16798042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two durations of triple-drug therapy in patients with uncomplicated brucellosis: A randomized controlled trial.
    Sofian M; Velayati AA; Aghakhani A; McFarland W; Farazi AA; Banifazl M; Eslamifar A; Ramezani A
    Scand J Infect Dis; 2014 Aug; 46(8):573-7. PubMed ID: 24934986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy of gentamicin for 5 days plus doxycycline for 8 weeks versus streptomycin for 2 weeks plus doxycycline for 45 days in the treatment of human brucellosis: a randomized clinical trial.
    Roushan MR; Amiri MJ; Janmohammadi N; Hadad MS; Javanian M; Baiani M; Bijani A
    J Antimicrob Chemother; 2010 May; 65(5):1028-35. PubMed ID: 20215128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiological features of brucellosis and factors affecting its treatment failure and relapse in Qom Province, Iran.
    Mohammadbeigi A; Saghafipour A; Hamta A; Khazaei S; Maghsoudi A; Shams S
    Ghana Med J; 2021 Sep; 55(3):206-212. PubMed ID: 35950176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features, complications and treatment outcome of childhood brucellosis in central Greece.
    Tsolia M; Drakonaki S; Messaritaki A; Farmakakis T; Kostaki M; Tsapra H; Karpathios T
    J Infect; 2002 May; 44(4):257-62. PubMed ID: 12099734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiological characteristics of human brucellosis in Hamadan Province during 2009-2015: results from the National Notifiable Diseases Surveillance System.
    Nematollahi S; Ayubi E; Karami M; Khazaei S; Shojaeian M; Zamani R; Mansori K; Gholamaliee B
    Int J Infect Dis; 2017 Aug; 61():56-61. PubMed ID: 28602765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxycycline-rifampin versus doxycycline-rifampin-gentamicin in treatment of human brucellosis.
    Mile B; Valerija K; Krsto G; Ivan V; Ilir D; Nikola L
    Trop Doct; 2012 Jan; 42(1):13-7. PubMed ID: 22290107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human brucellosis in Northern Saudi Arabia.
    Fallatah SM; Oduloju AJ; Al-Dusari SN; Fakunle YM
    Saudi Med J; 2005 Oct; 26(10):1562-6. PubMed ID: 16228056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of brucellosis relapse and complications registry: a study protocol.
    Keramat F; Mamani M; Adabi M; Khazaei S; Shivapoor Z; Karami M
    J Prev Med Hyg; 2021 Jun; 62(2):E496-E500. PubMed ID: 34604591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human brucellosis: do we need to revise our therapeutic policy?
    El Miedany YM; El Gaafary M; Baddour M; Ahmed I
    J Rheumatol; 2003 Dec; 30(12):2666-72. PubMed ID: 14719211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological features of human brucellosis in central Iran, 2006-2011.
    Zeinalian Dastjerdi M; Fadaei Nobari R; Ramazanpour J
    Public Health; 2012 Dec; 126(12):1058-62. PubMed ID: 22884862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind study to assess the optimal duration of doxycycline treatment for human brucellosis.
    Solera J; Geijo P; Largo J; Rodriguez-Zapata M; Gijón J; Martinez-Alfaro E; Navarro E; Macia MA;
    Clin Infect Dis; 2004 Dec; 39(12):1776-82. PubMed ID: 15578399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selected epidemiological features of human brucellosis in Yazd, Islamic Republic of Iran: 1993-1998.
    Salari MH; Khalili MB; Hassanpour GR
    East Mediterr Health J; 2003; 9(5-6):1054-60. PubMed ID: 16450537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sero-diagnosis of human brucellosis among TB suspected patients.
    Qazilbash AA; Bari A
    J Pak Med Assoc; 1997 Oct; 47(10):243-6. PubMed ID: 9529848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.